This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgan-Linnell, S. K.
Right arrow Articles by Zechiedrich, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan-Linnell, S. K.
Right arrow Articles by Zechiedrich, L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2007, p. 4205-4208, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00647-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Contributions of the Combined Effects of Topoisomerase Mutations toward Fluoroquinolone Resistance in Escherichia coli{triangledown}

Sonia K. Morgan-Linnell and Lynn Zechiedrich*

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030-3411

Received 16 May 2007/ Returned for modification 3 July 2007/ Accepted 27 July 2007

In defined, isogenic strains, at least three mutations, two of which must be in gyrA, were required to exceed the CLSI breakpoint for fluoroquinolone resistance. Strains with double mutations in both gyrA and parC had even higher MICs of fluoroquinolones than strains with totals of three mutations.

* Corresponding author. Mailing address: Department of Molecular Virology and Microbiology, Baylor College of Medicine, One Baylor Plaza, Mail-stop BCM-280, Houston, TX 77030-3411. Phone: (713) 798-5126. Fax: (713) 798-7375. E-mail: elz{at}bcm.edu

{triangledown} Published ahead of print on 6 August 2007.

Antimicrobial Agents and Chemotherapy, November 2007, p. 4205-4208, Vol. 51, No. 11
0066-4804/07/$08.00+0     doi:10.1128/AAC.00647-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Singh, R., Ledesma, K. R., Chang, K.-T., Hou, J.-G., Prince, R. A., Tam, V. H. (2009). Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother 64: 556-562 [Abstract] [Full Text]  
  • Almahmoud, I., Kay, E., Schneider, D., Maurin, M. (2009). Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila. J Antimicrob Chemother 64: 284-293 [Abstract] [Full Text]  
  • Becnel Boyd, L., Maynard, M. J., Morgan-Linnell, S. K., Horton, L. B., Sucgang, R., Hamill, R. J., Jimenez, J. R., Versalovic, J., Steffen, D., Zechiedrich, L. (2009). Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical Isolates. Antimicrob. Agents Chemother. 53: 229-234 [Abstract] [Full Text]  
  • Morgan-Linnell, S. K., Becnel Boyd, L., Steffen, D., Zechiedrich, L. (2009). Mechanisms Accounting for Fluoroquinolone Resistance in Escherichia coli Clinical Isolates. Antimicrob. Agents Chemother. 53: 235-241 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»